Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 5/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL52380 | 0.82 | CYP2C19 (0.48) | BCL2MCL1ALDH1A1ERCC1FEN1 | |
| SCHEMBL26672974 | 0.78 | GDA (0.41) | GDABCL2MCL1ALDH1A1PARP1 | |
| SCHEMBL343999 | 0.77 | GDA (0.63) | GDAALDH1A1PARP1CYP2C19HSD17B10 | |
| SCHEMBL3025277 | 0.77 | — | — | |
| SCHEMBL823314 | 0.76 | ERCC1 (0.47) | BCL2MCL1ALDH1A1ERCC1FEN1 | |
| Hydrochloric Acid SCHEMBL10712747 | 0.75 | GDA (0.45) | GDAALDH1A1PARP1CYP2C19HSD17B10 | |
| Hydrochloric Acid SCHEMBL3986298 | 0.75 | GDA (0.61) | GDAALDH1A1PARP1CYP2C19HSD17B10 | |
| Water SCHEMBL11020981 | 0.75 | GDA (0.45) | GDAALDH1A1PARP1CYP2C19HSD17B10 | |
| Hydrochloric Acid SCHEMBL16467994 | 0.73 | GDA (0.44) | GDAALDH1A1PARP1CYP2C19HSD17B10 | |
| SCHEMBL8024 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2012-04-19 | — | — | US | claimed |
| WO-2010114919-A2 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | STC.UNM (US) | 2010-10-07 | — | — | WO | claimed |
| EP-3548031-B1 | TRICYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11358711-B2 | Tetracyclic heterocycle compounds useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3377065-B1 | SPIROCYCLIC PYRIDOTRIAZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-110214142-B | Tetracyclic heterocyclic compounds useful as HIV integrase inhibitors | 默沙东公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3397639-B1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3389380-B1 | SPIROCYCLIC QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3377066-B1 | AMIDO-SUBSTITUTED PYRIDOTRIAZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10934312-B2 | Tricyclic heterocycle compounds useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3330272-B1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20050025774-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase | MSD ITALIA S.R.L. (IT) | 2005-02-03 | — | — | US | disclosed |
| US-20050025774-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase | MSD ITALIA S.R.L. (IT) | 2005-02-03 | — | — | US | disclosed |
| EP-1441735-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2004-08-04 | — | — | EP | disclosed |
| EP-1441735-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2004-08-04 | — | — | EP | disclosed |
| WO-2004058756-A1 | TETRAHYDRO-4H-PYRIDO[1,2-A]PYRIMIDINES AND RELATED COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004047725-A2 | 8-HYDROXY-1-OXO-TETRAHYDROPYRROLOPYRAZINE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO. INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004024078-A2 | DIHYDROXYPYRIDOPYRAZINE-1,6-DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2003035077-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003035077-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | RNASE1, DCLRE1B, FEN1 | GDA 224/4885BCL2 2022/4885MCL1 1385/4885 |
| US-11358711-B2 | Tetracyclic heterocycle compounds useful as HIV integrase inhibitors | TYMP, IDH1, CCNE1 | GDA 299/4885BCL2 2514/4885MCL1 1139/4885 |
| US-10934312-B2 | Tricyclic heterocycle compounds useful as HIV integrase inhibitors | CCNY, CDK11A, TK1 | GDA 99/4885BCL2 3237/4885MCL1 1979/4885 |
| US-20050025774-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase | IMPDH1, CCNI, REV1 | GDA 792/4885BCL2 4644/4885MCL1 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.